Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

9.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.2K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

352
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
352
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Internet-based problem solving therapy improves depressive and dialysis related physical symptoms in hemodialysis patients under 65 years of age: A post-hoc secondary subgroup analysis of a cluster randomized controlled trial.

General hospital psychiatry·2026
Same author

Validation of Two Screening Tools for Anxiety in Hemodialysis Patients.

Journal of personalized medicine·2022
Same author

A pragmatic approach for implementation of value-based healthcare in Amsterdam UMC, the Netherlands.

BMC health services research·2022
Same author

Depression, anxiety and quality of life of hemodialysis patients before and during the COVID-19 pandemic.

Journal of psychosomatic research·2022
Same author

Internet-based treatment for depressive symptoms in hemodialysis patients: A cluster randomized controlled trial.

General hospital psychiatry·2022
Same author

The effect of natriuretic C-type peptide and its change over time on mortality in patients on haemodialysis or haemodiafiltration.

Clinical kidney journal·2021

Related Experiment Video

Updated: May 3, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

15.0K

Pharmacologic targets and peritoneal membrane remodeling.

Karima Farhat1, Andrea W D Stavenuiter, Rob H J Beelen

  • 1Department of Nephrology,1 VU University Medical Center, and Department of Molecular Cell Biology and Immunology,2 VU University, Amsterdam, Netherlands.

Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
|February 15, 2014
PubMed
Summary

Peritoneal dialysis (PD) can cause peritoneal membrane changes. This review explores pharmacologic treatments to reverse PD-related damage and extend dialysis treatment duration.

Keywords:
Therapeutic interventions

More Related Videos

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

2.9K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

1.1K

Related Experiment Videos

Last Updated: May 3, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

15.0K
A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

2.9K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

1.1K

Area of Science:

  • Nephrology
  • Membrane Biology
  • Pharmacology

Background:

  • Peritoneal dialysis (PD) is a vital renal replacement therapy.
  • PD is associated with progressive peritoneal membrane alterations, termed peritoneal remodeling.
  • Factors like cytokines and PD fluids contribute to peritoneal damage.

Purpose of the Study:

  • To review pharmacologic interventions for peritoneal remodeling.
  • To assess strategies for mitigating PD-induced peritoneal membrane damage.
  • To explore methods for prolonging the efficacy of peritoneal dialysis.

Main Methods:

  • Literature review of studies on pharmacologic agents targeting peritoneal remodeling.
  • Analysis of research investigating interventions to reverse peritoneal damage.
  • Synthesis of data on treatments aimed at extending PD treatment duration.

Main Results:

  • Various pharmacologic agents show potential in mitigating peritoneal membrane changes.
  • Interventions may help reverse structural and functional alterations in the peritoneum.
  • Pharmacologic approaches could extend the viability of PD as a treatment option.

Conclusions:

  • Pharmacologic interventions offer promising avenues to manage PD-related peritoneal remodeling.
  • Targeting peritoneal damage may significantly improve long-term PD outcomes.
  • Further research is warranted to optimize these therapeutic strategies for clinical use.